Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033416 | 0.92 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18995851 | 0.88 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16033933 | 0.88 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18995862 | 0.87 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL30077950 | 0.82 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL15068371 | 0.82 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL15065525 | 0.82 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL15068348 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL30078022 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL24081283 | 0.80 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20160038474-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038474-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038474-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| WO-2015031284-A1 | FORMULATIONS COMPRISING WETTING AGENTS AND COMPOUNDS FOR THE MODULATION OF HEMOGLOBIN (S) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20140271591-A1 | Compositions and methods for the modulation of hemoglobin (s) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271591-A1 | Compositions and methods for the modulation of hemoglobin (s) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271591-A1 | Compositions and methods for the modulation of hemoglobin (s) | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038474-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S) | HBB, HBG2, HBG1 | CYP1A2 285/4885CYP3A4 409/4885CYP2C8 494/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
| US-20140271591-A1 | Compositions and methods for the modulation of hemoglobin (s) | HBB, HBG2, HBG1 | CYP1A2 598/4885CYP3A4 309/4885CYP2C8 539/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.